WO2023282354A1 - エビ目の生物の飼育用組成物、およびエビ目感染症に対する予防または治療用組成物 - Google Patents

エビ目の生物の飼育用組成物、およびエビ目感染症に対する予防または治療用組成物 Download PDF

Info

Publication number
WO2023282354A1
WO2023282354A1 PCT/JP2022/027145 JP2022027145W WO2023282354A1 WO 2023282354 A1 WO2023282354 A1 WO 2023282354A1 JP 2022027145 W JP2022027145 W JP 2022027145W WO 2023282354 A1 WO2023282354 A1 WO 2023282354A1
Authority
WO
WIPO (PCT)
Prior art keywords
nite
shrimp
composition
bacterial cell
shrimps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/027145
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
幹雄 青木
和樹 味方
敏裕 甲斐
育生 廣野
秀裕 近藤
紗奈 松本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokyo University of Marine Science and Technology NUC
Sumitomo Chemical Co Ltd
Original Assignee
Tokyo University of Marine Science and Technology NUC
Sumitomo Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo University of Marine Science and Technology NUC, Sumitomo Chemical Co Ltd filed Critical Tokyo University of Marine Science and Technology NUC
Priority to KR1020247003673A priority Critical patent/KR20240032900A/ko
Priority to EP22837768.5A priority patent/EP4368201A4/en
Priority to CN202280048094.2A priority patent/CN117677300A/zh
Priority to CA3226312A priority patent/CA3226312A1/en
Priority to AU2022308954A priority patent/AU2022308954A1/en
Priority to JP2023533203A priority patent/JPWO2023282354A1/ja
Priority to US18/576,842 priority patent/US20240335486A1/en
Publication of WO2023282354A1 publication Critical patent/WO2023282354A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K61/00—Culture of aquatic animals
    • A01K61/50—Culture of aquatic animals of shellfish
    • A01K61/59—Culture of aquatic animals of shellfish of crustaceans, e.g. lobsters or shrimps
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum

Definitions

  • the present invention relates to a composition for breeding shrimps and a composition for prevention or treatment against shrimps infections.
  • the present invention also relates to a method for rearing shrimp organisms using the above composition.
  • EMS/AHPND early death syndrome/acute hepatopancreatic necrosis
  • Patent Document 1 discloses a vaccine composition that induces immunity against Vibrio in shrimp.
  • a vaccine containing Vibrio parahaemolyticus which is the causative agent of EMS/AHPND, has not yet been developed, and the preventive and therapeutic effects of the vaccine composition on EMS/AHPND are unknown.
  • International Publication No. WO 2019/059027 discloses that EMS/AHPND can be prevented and treated by ingesting an orally administered composition containing 5-aminolevulinic acid to organisms of the order Eurasian order to promote their growth. disclosed.
  • Non-Patent Document 1 describes Lactobacillus plantarum SGLAB01 strain and Lactococcus lactis SGLAB02 strain derived from shrimp intestine, or A method of activating the biological defense system and increasing the resistance to EMS/AHPND by using a probiotic (live bacteria)-added feed of the combination has been reported.
  • the growth promoters and probiotics described above do not show direct antibacterial activity against EMS/AHPND-causing bacteria, but indirectly increase resistance to EMS/AHPND by acting on the biological defense system of shrimp.
  • the purpose of the present invention is to provide a method for suppressing prawns infection with less impact on the environment and less toxicity to humans.
  • the present invention relates to items exemplified below.
  • a shrimp organism containing at least one bacterial cell or bacterial cell culture selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201, or an extract thereof Breeding composition.
  • Micromp of the genus Vibrio containing at least one bacterial cell or bacterial cell culture selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201, or an extract thereof
  • a preventive or therapeutic composition for eye infections is exemplified below.
  • the composition according to [2] wherein the lobster infection includes early death syndrome/acute hepatopancreatic necrosis.
  • shrimp order includes the Kuruma shrimp family.
  • At least one bacteria selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201, a bacterial cell or a bacterial cell culture, or an extract thereof is ingested by a shrimp organism.
  • a method of rearing an organism of the order Ebiformes comprising: [8] Shrimp in breeding water containing at least one bacterial cell or bacterial cell culture selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201, or an extract thereof A method of rearing an organism of the order Eurasian order comprising immersing the organism. [9] At least one bacterial cell or bacterial cell culture selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201, or an extract thereof, is ingested by a shrimp organism A prophylactic or therapeutic method for a shrimp infection caused by Vibrio spp.
  • [10] Shrimp in breeding water containing at least one bacterial cell or bacterial cell culture selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201, or an extract thereof
  • a prophylactic or therapeutic method for Vibrio spp. prawn infection comprising immersing the organism.
  • a method for raising shrimps comprising dropping the composition according to any one of [1] to [6] into water for raising shrimps.
  • infectious diseases can be suppressed by directly exhibiting antibacterial activity against causative bacteria of porphyrinus infections.
  • FIG. 2 shows (A) colony shape and (B) Gram staining results of NITE BP-03199 in Experiment 1.
  • FIG. Fig. 2 shows (A) colony shape and (B) Gram staining results of NITE BP-03200 in Experiment 2.
  • Fig. 10 shows (A) colony shape and (B) Gram staining results of NITE BP-03201 in Experiment 3. It is a figure explaining the antibacterial activity evaluation test (plate culture) with respect to the Vibrio genus of experiment 4.
  • FIG. 10 is a graph showing the inhibitory effect of NITE BP-03200 and NITE BP-03201 on shrimp infection caused by Vibrio spp. in Experiment 7.
  • FIG. 10 is a graph showing the inhibitory effect of NITE BP-03201 on shrimp infection caused by Vibrio spp. in Experiment 8.
  • FIG. 8 shows (A) colony shape and (B) Gram staining results of NITE BP-03199 in Experiment 1.
  • composition for raising shrimps comprises at least one bacterial cell or fungus selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201. Including somatic cultures or extracts thereof.
  • the composition for raising shrimps according to the present invention can prevent or treat infectious diseases caused by Vibrio spp. of shrimps.
  • NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201 are respectively assigned accession number NITE BP-03199 (original deposit date: April 9, 2020), accession number NITE BP-03200 (original deposit date: April 9, 2020) and as accession number NITE BP-03201 (original deposit date: April 9, 2020), National Institute of Technology and Evaluation Patent Microorganism Depositary Center (NPMD, Address: 292-0818 Chiba It is a bacterium that has been internationally deposited under the Budapest Treaty at Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Prefecture.
  • NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201 are bacteria belonging to Lactobacillus plantarum, which is a kind of lactic acid bacteria.
  • the mycological properties of the above strains are shown in Tables 1 to 6 and FIGS. 1 to 3, which will be described later.
  • NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201 exist in the natural environment, they are considered to be highly safe when used for raising shrimp.
  • NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201 may be isolated bacteria.
  • the composition for breeding shrimps according to the present invention contains the above-mentioned lactic acid bacteria cells or cell cultures, or extracts thereof.
  • Bacteria may be isolated from the environment or may be cultured.
  • the cells may be dead cells or live cells.
  • the cells may exist in a culture medium, buffer solution, or the like, or may be concentrated to remove the liquid, a lyophilized product thereof, or a frozen stock.
  • the bacterial cell culture may contain bacterial secretions, metabolites, and the like.
  • Cell cultures include peptides, proteins, sugars, enzymes, organic acids produced by bacteria, and media containing these (liquid media and solid media).
  • the cell culture may be a supernatant obtained by culturing bacteria.
  • the culture supernatant can be obtained, for example, by removing bacteria from a liquid medium in which bacteria have been cultured by centrifugation, filtration, or the like.
  • NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201 can be cultured according to a normal culture method for lactic acid bacteria.
  • a typical culture method includes a method of culturing at a temperature of 30° C. using MRS (de Mann, Rogosa and Sharpe) liquid medium or MRS agar medium.
  • the bacterial cell or bacterial cell culture extract is prepared so as not to lose the antibacterial activity against the Vibrio spp. possessed by the lactic acid bacteria cell or bacterial cell culture.
  • Extracts can be obtained, for example, by subjecting bacterial cells or cell cultures to ultrasonic disruption, bead grinding, freeze-thawing, chemical lysis, or the like.
  • the extract may be obtained by salting-out, ultrafiltration, ion-exchange chromatography, liquid-phase extraction using an organic solvent, or the like, on the cells or cell culture. These treatments can be performed in combination as appropriate.
  • the extract may contain bacterial cell fragments, nucleic acids, peptides, proteins, sugars and enzymes. In the present specification, bacterial cells, bacterial cell cultures, or extracts thereof are also referred to as "microbial cell preparations.”
  • the shrimp order is also referred to as the order Decapoda, which is one of the taxonomic groups of crustaceans.
  • the order Ebina includes shrimps, crabs, hermit crabs, and the like.
  • the order Ebina includes the order Dendrobranchiata and the order Pleocyemata.
  • the suborder Sergestoidea, Penaeidea, Sicyoniidae, Solenoceridae, Aristeidae and Benthesicymidae.
  • the tiger prawn family includes bull shrimp (commonly known as black tiger) (Penaeus monodon), white-footed shrimp (commonly known as Litopenaeus vannamei), blue-spotted shrimp (Fennelopenaeus chinensis), tiger prawn (Marsupenaeus japonicus), prawn (Melicertusus lattis). , Metapenaeus joyneri, Metapenaeus moyebi, Metapenaeopsis barbata, Metapenaeopsis lata, Penaeus semisulcatus, Trachysalambria curvirostris, and the like.
  • the Kuruma shrimp family includes many important species in the shrimp farming industry.
  • the suborder Stenopodidea, Caridea, Polychelida, Achelata, Astacidea, Glypheidea, and Astacidea Including the order Axiidea, Gebiidea, Hermit crab Anomura and Brachyura.
  • the composition for breeding shrimps may be an orally administered composition.
  • the composition for oral administration is not particularly limited as long as it is a composition that is orally administered to organisms of the order Eurasian order.
  • the composition for rearing the shrimps may be a feed or feed additive for the shrimps.
  • the orally administered composition is administered to an environment (e.g., breeding water) in which organisms of the order Shrimp are bred, and the bacterial cell preparation of the lactic acid bacterium dissolves into the environment, and the organisms of the order Shrimp are bred in the environment. May be taken orally.
  • the composition for oral administration of an organism of the order Eurasian order containing the above-described bacterial cell preparation of lactic acid bacteria can prevent or treat infections caused by Vibrio spp.
  • the feed for shrimps may contain any component as long as it is a component normally used for rearing or culturing organisms of the shrimps, and may be manufactured by any manufacturing method.
  • the composition of the diet for shrimps can be appropriately selected depending on the species of shrimps and the growth stage.
  • the prawn feed may contain a protein source such as squid meal, krill meal, fish meal, soybean meal, corn gluten meal, and binders such as gluten and starch.
  • the feed for prawns may contain known carriers or additives that are acceptable for feed, and include erythromycin preparations, ampicillin preparations, praziquantel preparations, lysozyme chloride preparations, oxytetracycline hydrochloride preparations, spiramycin preparations, and sodium nifurstyrene preparations.
  • lincomycin hydrochloride preparations preparations, flumekine preparations, and glutathione preparations for aquatic products
  • vitamins such as vitamin C, vitamin B1, vitamin A, vitamin D, and vitamin E, and amino acids such as lysine, methionine, and histidine pigments such as beta-carotene, astaxanthin, and canthaxanthin
  • minerals such as calcium and silicic acid; trace metals;
  • the feed for shrimps may have any shape and size according to the type and size of the shrimps to be raised.
  • the feed for prawns may be, for example, powdered feed obtained by mixing and pulverizing dry raw materials, solidified feed obtained by solidifying powder (dry pellet), pasty feed containing water (moist pellet), and the like. .
  • a general powder feed for prawn farming is mixed with the cell preparation of the lactic acid bacterium.
  • the mixture is shaped, for example extruded using a pasta machine or syringe.
  • the molded product is dried at, for example, 60° C. to 65° C.
  • a general powder feed for shrimp farming is coated with the above lactic acid bacteria cell preparation, and a powdered shrimp farming liquid containing the above lactic acid bacteria cell preparation ( culture supernatant, etc.).
  • the amount of the lactic acid bacteria cell preparation contained in the feed for prawns is not particularly limited as long as it exhibits antibacterial activity against Vibrio spp. Any amount may be used as long as it is suitable for the concentration, breeding density, type of target shrimp, and the like.
  • the total amount of the bacterial cell preparation of the lactic acid bacterium in the lapidary feed may be, for example, 1 ⁇ 10 3 to 1 ⁇ 10 12 cfu (colony forming units)/g, or 1 ⁇ 10 4 to 1 ⁇ 10 12 cfu/g, or 1 ⁇ 10 5 to 1 ⁇ 10 12 cfu/g.
  • the colony-forming unit can be determined by an agar plate culture method.
  • the total amount (content ratio) of the bacterial cell preparation of lactic acid bacteria in the feed for prawns is 0.001% by mass to 50% by mass, preferably 0.001% by mass to 30% by mass, based on the weight of the feed. It may be preferably 0.01% by mass to 30% by mass, more preferably 0.01% by mass to 10% by mass. The total amount can be weighed with a balance or the like.
  • the feed additive for shrimps is not particularly limited as long as it is an additive that can be added to general feed for farming shrimps.
  • the feed additive may be liquid or powder, and may be lyophilized.
  • the feed additive may be the cell preparation of the lactic acid bacterium itself.
  • the feed additive may include a liquid, a spreading agent, etc. for facilitating the attachment, absorption or mixing of the lactic acid bacteria cell preparation with the feed for shrimps.
  • the feed additive is preferably added to the feed so that the total amount of the bacterial cell preparation contained in the feed is within the above range.
  • the feed for prawns containing the lactic acid bacteria cell preparation may be fed once a day or divided into multiple times.
  • the feed containing the cell preparation of lactic acid bacteria may be fed once every few days.
  • the period during which the feed containing the above-mentioned lactic acid bacteria cell preparation is fed can be appropriately selected according to the type of shrimp order of interest.
  • the feed containing the cell preparation of lactic acid bacteria may be continuously fed during the entire cultivation (breeding) period, or may be fed only during a part of the period.
  • the “partial period” may be, for example, 10% or more, 20% or more, 30% or more, 50% or more, 70% or more, or 90% or more of the entire breeding period.
  • the upper limit of the above-mentioned "partial period” is not particularly limited, but for example, it may be less than 100% of the entire breeding period, or 99% or less. good.
  • the period of feeding the feed containing the lactic acid bacteria cell preparation may be, for example, 1 to 4 months, or may be about 2 months. With regard to the feed containing the cell preparation of lactic acid bacteria, the feeding may be continued and interrupted for any period of time.
  • the composition for rearing of the shrimp can be given to organisms of the shrimp.
  • Examples of the method of providing a composition for rearing of the shrimps to the shrimps include a method of mixing the water for rearing the shrimps and the composition for rearing the shrimps.
  • Methods for mixing the water for rearing shrimps and the composition for rearing shrimps include a method of dropping the composition for rearing shrimps into water, and a composition for rearing shrimps. Examples include a method of pouring water into a breeding tank in which an object is placed, and a method of adding a composition for breeding shrimps dissolved in water to water for breeding shrimps.
  • the composition for rearing the shrimps may be automatically fed to the shrimps at regular intervals.
  • the shrimp feed may be supplied by dropping into the water in which the organisms of the shrimp are raised, or may be supplied automatically at regular intervals.
  • the composition for breeding shrimps may be an immersion administration composition.
  • the immersion administration composition may be a breeding water or a breeding water additive.
  • the rearing water may be any liquid commonly used for rearing Eurasian organisms and may be fresh, brackish or seawater (including artificially prepared seawater). Rearing of shrimps may be done in aquaculture ponds or aquariums in a natural environment.
  • the breeding water may be aerated.
  • the breeding water containing the cell preparation of lactic acid bacteria has an antibacterial activity against Vibrio. Infectious diseases caused by Vibrio can be suppressed in the organisms of the order Eurasian order immersed in this breeding water.
  • the content of the lactic acid bacteria cell preparation in the breeding water is not particularly limited as long as it exhibits antibacterial activity against Vibrio spp.
  • the amount may be suitable for the density, the type of shrimp order to be processed, and the like.
  • the total amount (content) of the cell preparation of lactic acid bacteria in the breeding water may be, for example, 1 ⁇ 10 2 to 1 ⁇ 10 8 cfu/mL, or 1 ⁇ 10 3 to 1 ⁇ 10 8 cfu/mL. or 1 ⁇ 10 4 to 1 ⁇ 10 8 cfu/mL.
  • the colony-forming unit can be determined by an agar plate culture method.
  • the total concentration of the lactic acid bacteria cell preparation contained in the breeding water is not particularly limited, and may be 0.1 to 100,000 ppm, 1 to 100,000 ppm, or 10 to 100 ppm. ,000 ppm.
  • the total amount of the cell preparation of lactic acid bacteria can be weighed with a balance or the like. Based on the determined total amount, it is possible to calculate the concentration from the mass ratio to the breeding water.
  • the breeding water additive is not particularly limited as long as it is an additive that can be added to common breeding water for shrimp.
  • the breeding water additive may be liquid or powder, and may be lyophilized.
  • the breeding water additive may be the cell preparation itself of the lactic acid bacteria.
  • the breeding water additive is preferably added to the breeding water so that the total amount of the bacterial cell preparation contained in the breeding water is within the above range.
  • the breeding water additive may be added to the breeding water before starting the breeding of the shrimp-like organisms, or may be added to the breeding water during the breeding of the shrimp-like organisms.
  • Examples of the method of adding the breeding water additive to the breeding water include the same methods as the method of mixing the above-described water for breeding shrimps with the composition for breeding shrimps.
  • the breeding water additive may be dropped into the water in which the shrimps are reared, or may be fed automatically at regular intervals.
  • the period for immersing the shrimp organisms in the breeding water containing the lactic acid bacteria cell preparation can be selected as appropriate.
  • the shrimp organisms may be continuously raised in the breeding water containing the above preparation of lactic acid bacteria over the entire period of raising the shrimp organisms, and the shrimp organisms may be kept in this breeding water only for a part of the period. may be immersed.
  • the period of breeding in breeding water containing the cell preparation of lactic acid bacteria may be, for example, 1 month to 4 months, or may be about 2 months. Breeding in breeding water containing the cell preparation of lactic acid bacteria may be continued and interrupted for any period of time.
  • One embodiment of the present invention relates to at least one bacterial cell selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201 or The use of bacterial cell cultures or their extracts.
  • a method for rearing shrimps comprises at least one bacterial cell or cell culture selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201. or extracts thereof to organisms of the order Estria. Administration may be oral administration or immersion administration.
  • a method for rearing shrimps comprises at least one bacterial cell or cell culture selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201. or extracts thereof to organisms of the order Estria.
  • the bacterial cell preparation of the lactic acid bacterium may be supplied as a composition for rearing the organisms of the order Estria.
  • a method for rearing shrimps comprises at least one bacterial cell or cell culture selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201. including immersing the organisms of the order Estrella in breeding water containing the substances or extracts thereof. Breeding water containing the cell preparation of the lactic acid bacterium may be supplied as a composition for breeding the organisms of the order Estrella.
  • a composition for rearing a shrimp organism may be provided according to the method of mixing the water for rearing a shrimp organism and the composition for rearing a shrimp organism described above. good.
  • the composition for raising shrimps may be dropped into the water in which shrimps are raised, or may be automatically supplied at regular intervals. good.
  • One embodiment of the present invention is a cell or cell culture of at least one bacterium selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201 in the rearing of shrimps organisms or Use of these extracts.
  • the preventive or therapeutic composition for Vibrio infections caused by Vibrio is at least one selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201. Bacterial cells or cell cultures or extracts thereof are included.
  • a prophylactic or therapeutic composition may be a veterinary drug.
  • NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201 have antibacterial activity against Vibrio spp. can.
  • NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201 can be used to prevent or treat Vibrio seriformes infections.
  • treatment includes alleviation of symptoms, amelioration of symptoms, and complete cure.
  • the above lactic acid bacteria have direct antibacterial activity against the causative bacteria of infectious diseases, and the inhibitory mechanism of infectious diseases does not depend on the host. Infectious diseases can be suppressed.
  • the use of the lactic acid bacteria makes it possible to more stably cultivate shrimps.
  • EMS/AHPND caused by Vibrio parahaemolyticus is an example of a shrimp infection caused by Vibrio spp.
  • Vibrio parahaemolyticus which causes EMS/AHPND in organisms of the shrimp order, is of the same species as Vibrio parahaemolyticus, which causes food poisoning in humans, but is a different type of bacterium.
  • Other Vibrio spp. that cause infections in organisms of the order Eurasianum include V. nigripulchritudo, V. penaeicida, V. alginolyticus), V. anguillarum, V.
  • campbelli V. damsella, V. fischeri, V.; harveyi, V.; logei, V. mediterrani, V. ordalii, V. orientalis, V. pelagicus, V. superbus, V. vulnificus, V. fluvialis, V. cholerae and the like.
  • V. nigripulchritudo and V. Massive deaths of prawn organisms due to penaeicida infections have also been reported.
  • the prophylactic or therapeutic composition may be an orally administered composition, and may be administered to the shrimp in the form of a feed or feed additive.
  • Prophylactic or therapeutic compositions may comprise ingredients that can be included in orally administered compositions used for rearing organisms of the order Estrella.
  • the prophylactic or therapeutic composition may further comprise a component that has known antibacterial activity against Vibrio or a component that enhances the immune activity of organisms of the order Eurasian order.
  • the form, method of manufacture and method of administration of the prophylactic or therapeutic composition may be the same as the form, method of manufacture and method of administration of the composition for oral administration described above.
  • the content of the bacterial cell preparation of lactic acid bacteria in the preventive or therapeutic composition is not particularly limited as long as it can suppress infectious diseases caused by Vibrio spp. may be in the same range as the content in
  • the prophylactic or therapeutic composition may be breeding water or a breeding water additive.
  • the prophylactic or therapeutic composition that is the rearing water or rearing water additive may be used or added in the same manner as the rearing water or rearing water additive used in the rearing of the above-mentioned shrimps.
  • the content of the bacterial cell preparation of lactic acid bacteria in the preventive or therapeutic composition is not particularly limited as long as it can suppress infectious diseases caused by Vibrio spp. It may be in the same range as the amount.
  • One embodiment of the present invention is at least one selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201 in the manufacture of prophylactic or therapeutic compositions against Vibrio spp. is the use of bacterial cells or bacterial cell cultures or extracts thereof.
  • a prophylactic or therapeutic method for Vibrio spp. infections caused by Vibrio comprises at least one bacterium selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201. This includes administering the cells or cell cultures or extracts thereof to organisms of the order Estria. Administration may be oral administration or immersion administration.
  • a prophylactic or therapeutic method for Vibrio spp. infections caused by Vibrio comprises at least one bacterium selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201. It includes ingesting the fungus body, fungal culture, or an extract thereof to a shrimp.
  • the cell preparation of lactic acid bacteria may be supplied to organisms of the order Eurasian order as the preventive or therapeutic composition.
  • a prophylactic or therapeutic method for Vibrio spp. infections caused by Vibrio comprises at least one bacterium selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201. It includes immersing a shrimp organism in breeding water containing fungal cells, fungal cell cultures, or extracts thereof. Breeding water containing the cell preparation of lactic acid bacteria may be supplied as the preventive or therapeutic composition.
  • One embodiment of the present invention is the use of at least one bacterium selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201 for the prevention or treatment of Vibrio order infections. It is the use of cells or cell cultures or extracts thereof.
  • the Vibrio spp. growth inhibitor or bactericide is at least one bacterial cell selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201 or Contains bacterial cell cultures or extracts thereof.
  • the growth inhibitor or fungicide may be the same as the composition for breeding shrimps.
  • the antiproliferative agent or bactericidal agent may further comprise a substance having antibacterial activity against Vibrio.
  • the content of the lactic acid bacteria cell preparation contained in the Vibrio spp. growth inhibitor or disinfectant is not particularly limited, but may be, for example, 1 ⁇ 10 3 to 1 ⁇ 10 12 cfu/mL, or 1 ⁇ It may be from 10 5 to 1 ⁇ 10 12 cfu/mL, or from 1 ⁇ 10 7 to 1 ⁇ 10 12 cfu/mL.
  • the concentration of the lactic acid bacteria cell preparation contained in the growth inhibitor or disinfectant for Vibrio spp. is not particularly limited, and may be 1 to 1,000,000 ppm, 10,000 to 1,000,000 ppm.
  • the above lactic acid bacteria cell preparation can suppress or kill the growth of Vibrio spp. parahaemolyticus, V. nigripulchritudo and V. inhibits the growth of or kills at least one species selected from penaeicida.
  • the method for inhibiting the growth or sterilization of Vibrio spp. includes at least one bacterial cell or fungus selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201 Contacting somatic cultures or extracts thereof with Vibrio.
  • the method of contacting the lactic acid bacteria cell preparation with the Vibrio spp. is not particularly limited.
  • the lactic acid bacterium cell preparation may be added to water in which the Vibrio spp.
  • the object to be treated may be immersed in a liquid containing the cell preparation of lactic acid bacteria, or a host infected with Vibrio may be allowed to ingest a composition containing the cell preparation of lactic acid bacteria.
  • the cell preparation of lactic acid bacteria may be used in the form of a growth inhibitor for Vibrio or a bactericide.
  • One embodiment of the present invention is at least one bacterial cell selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201 in the production of Vibrio growth inhibitors or fungicides Alternatively, it is the use of bacterial cell cultures or extracts thereof.
  • One embodiment of the present invention is at least one bacterial cell or fungus selected from NITE-BP-03199, NITE-BP-03200 and NITE-BP-03201 for growth inhibition or sterilization of Vibrio spp. The use of somatic cultures or extracts thereof.
  • Example 1 Separation and identification of NITE BP-03199
  • the isolation source (lembu) was triturated with sterile water.
  • the homogenate was appropriately diluted and added to 1/2 MRS liquid medium for enrichment culture.
  • the enriched culture was smeared on a calcium carbonate-containing MRS agar medium to isolate microorganisms that formed halos.
  • this isolate will be referred to as isolate A.
  • Suspension of isolate A cultures in hydrogen peroxide did not generate bubbles.
  • Isolate A was confirmed to be a lactic acid bacterium because it did not have catalase activity.
  • Isolate A was identified by 16S rRNA gene analysis, morphological observation, and physiological and biochemical characterization tests.
  • 16S rRNA gene analysis Genomic DNA was extracted from the isolate A, and the resulting genomic DNA was used as a template for cloning forward primer 9F and cloning reverse primer 1510R (Yoshiyoshi Nakagawa et al.: Genetic analysis method of 16S rRNA gene.
  • PCR amplification of the 16S rRNA gene was performed using a nucleotide sequencing method, Actinomycetes Society of Japan, Classification and Identification of Actinomycetes, 88-117 pp. Japan Society Office, 2001).
  • PCR amplification was performed using Tks Gflex DNA polymerase (manufactured by Takara Bio Inc.), and the amplified product after PCR was purified.
  • a cycle sequencing reaction was performed using the purified amplified product after PCR.
  • the cycle sequencing reaction was performed using BigDye Terminator v3.1 Cycle Sequencing Kit.
  • the resulting reaction solution was purified, and the purified solution was subjected to DNA sequence analysis (3130xl DNA Analyzer) to determine the base sequence of the 16S rRNA gene of the template DNA extracted from isolate A.
  • Sequence analysis primers include 9F, 515F, 1099F, 536R, 926R, and 1510R (Yoshiyoshi Nakagawa et al.: Gene analysis method 16S rRNA gene sequencing method, Actinomycetes Society of Japan, Classification and Identification of Actinomycetes, 88 -117 pp. Japan Society Administrative Center, 2001) was used.
  • the base sequence of the 16S rRNA gene of isolate A was identified as a microorganism identification database DB-BA15.0 (manufactured by Techno Suruga Lab), an international base sequence database A BLAST homology search was performed against (DDBJ/ENA(EMBL)/GenBank).
  • the nucleotide sequence of the 16S rRNA gene of isolate A has 100.0% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus pentosus (JCM1558), Lactobacillus plantarum subsp.
  • isolate A formed circular colonies.
  • isolate A was positive for Gram staining.
  • Tables 1 and 2 show the results of physiological/biochemical property tests and fermentability tests of isolate A. Isolate A was a non-motile Gram-positive bacillus, did not form spores, was negative in catalase and oxidase reactions, and fermented glucose. These properties were consistent with those of the genus Lactobacillus, for which the possibility of attribution was shown as a result of 16S rDNA partial nucleotide sequence analysis.
  • isolate A fermented galactose, fructose, ⁇ -methyl-D-mannoside and melezitose, etc., but did not ferment glycerol, D-xylose, etc.
  • Isolate A showed no arginine dihydrolase activity and grew at 15°C. These properties were attributed to L. cerevisiae, whose attribution was suggested as a result of 16S rDNA partial nucleotide sequence analysis.
  • pentosus and L Among L. plantarum, L. plantarum shows no fermentation of glycerol and D-xylose. Unlike L. pentosus, L. It matched the properties of plantarum. Therefore, isolate A was found to be a novel isolate belonging to Lactobacillus plantarum. The isolate A was internationally deposited as NITE BP-03199.
  • Isolate B was isolated by the same method as in Experiment 1, except that pandanus was used as the isolation source. Identification of isolate B was performed by the same method as in Experiment 1.
  • the nucleotide sequence of the 16S rRNA gene of isolate B has 99.87% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus pentosus (JCM1558), Lactobacillus plantarum subsp. It showed 99.87% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus (JCM1149) and 99.66% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus paraplantarum (DSM10667). However, there was no microorganism with a 16S rRNA gene that completely matched the base sequence of the isolate B 16S rRNA gene.
  • isolate B formed circular colonies. As shown in FIG. 2B, isolate B was positive for Gram staining. Tables 3 and 4 show the results of physiological and biochemical property tests and fermentability tests of isolate B. Isolate B was a non-motile Gram-positive bacillus, did not form spores, was negative in catalase and oxidase reactions, and fermented glucose. These properties were consistent with those of the genus Lactobacillus, for which the possibility of attribution was shown as a result of 16S rDNA partial nucleotide sequence analysis.
  • isolate B fermented galactose, fructose, ⁇ -methyl-D-mannoside and melezitose, etc., but did not ferment glycerol, D-xylose, etc.
  • Isolate B showed no arginine dihydrolase activity and grew at 15°C. These properties were shown to be closely related as a result of 16S rDNA partial nucleotide sequence analysis.
  • pentosus and L Among L. plantarum, L. plantarum shows no fermentation of glycerol and D-xylose. Unlike L. pentosus, L. It matched the properties of plantarum. Therefore, isolate B was found to be a novel isolate belonging to Lactobacillus plantarum. Isolate B was internationally deposited as NITE BP-03200.
  • the base sequence of the 16S rRNA gene of isolate C has 99.93% identity to the base sequence of the 16S rRNA gene of Lactobacillus pentosus (JCM1558), Lactobacillus plantarum subsp. It showed 99.93% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus (JCM1149) and 99.73% identity to the nucleotide sequence of the 16S rRNA gene of Lactobacillus paraplantarum (DSM10667). However, there was no microorganism with a 16S rRNA gene that completely matched the base sequence of the isolate C 16S rRNA gene.
  • isolate C formed circular colonies. As shown in FIG. 3B, isolate C was positive for Gram staining. Tables 5 and 6 show the results of physiological and biochemical property tests and fermentability tests of isolate C. Isolate C was a non-motile Gram-positive bacillus, did not form spores, was negative in catalase and oxidase reactions, and fermented glucose. These properties were consistent with those of the genus Lactobacillus, for which the possibility of attribution was shown as a result of 16S rDNA partial nucleotide sequence analysis.
  • isolate C fermented galactose, fructose, melezitose, etc., but did not ferment glycerol, D-xylose, etc. Isolate C showed no arginine dihydrolase activity and grew at 15°C. These properties were attributed to L. cerevisiae, whose attribution was suggested as a result of 16S rDNA partial nucleotide sequence analysis.
  • pentosus and L. Among L. plantarum, L. plantarum shows no fermentation of glycerol and D-xylose. Unlike L. pentosus, L. It matched the properties of plantarum. Therefore, isolate C was found to be a novel isolate belonging to Lactobacillus plantarum. The isolate C was internationally deposited as NITE BP-03201.
  • NITE BP-03199, NITE BP-03200 and NITE BP-03201 caused growth inhibition circles to form in the growth medium of Vibrio spp. It was shown that all the cell cultures of NITE BP-03199, NITE BP-03200 and NITE BP-03201 can suppress the growth of Vibrio spp.
  • Experiment 5 Antibacterial activity evaluation test of lactic acid bacteria cell culture (liquid culture)] With regard to the cell culture of NITE BP-03201, which showed the highest antibacterial activity by the plate culture method, it was verified whether the growth of Vibrio spp. could be suppressed even in liquid. Experiment 5 differs from Experiment 4 in that the Vibrio spp. was cultured in a liquid medium. The Vibrio strain used in Experiment 5 is the same as in Experiment 4.
  • NITE BP-03201 culture filtrate was prepared from a lactic acid bacteria culture with a turbidity of about 10 OD at a wavelength of 600 nm.
  • the number of Vibrio bacteria was calculated from the turbidity at a wavelength of 600 nm.
  • the Vibrio spp. proliferated about 1000-fold compared to before culturing.
  • no growth of Vibrio was observed in the sample to which the culture filtrate of NITE BP-03201 was added. It was shown that the cell culture of NITE BP-03201 can suppress the growth of Vibrio spp. even in liquid.
  • the culture filtrate of NITE BP-03201 was added and the sample was cultured for 18 hours. The supernatant was removed by centrifugation, and the collected bacteria (Vibrio spp.) were resuspended in 3HI medium and cultured for an additional 24 hours. No bacterial growth was observed after incubation. Since no growth of Vibrio bacteria was observed even after removal of the lactic acid bacteria cell culture, the cell culture of NITE BP-03201 has a bactericidal effect rather than a bacteriostatic effect on Vibrio spp. It has been suggested.
  • Example 6 Antibacterial activity evaluation test of lactic acid bacteria cell culture (sterilized seawater culture)] It was verified whether the cell cultures of NITE BP-03199, NITE BP-03200 and NITE BP-03201 have antibacterial activity against Vibrio. Experiment 6 differs from Experiment 4 in that the Vibrio bacteria were cultured in artificial seawater. In experiment 6, V . parahaemolyticus TUMSAT-D6 strain (AHPND strain) was used.
  • Vibrio spp. (2 ⁇ 10 9 cfu/mL) cultured in 3HI medium was suspended in artificial seawater to about 2 ⁇ 10 2 cfu/mL.
  • Artificial seawater was prepared using Marine Salt (Tetra) and sterilized using a 0.22 ⁇ m diameter filter.
  • MRS Broth which is a medium for lactic acid bacteria, was added. The mixture was placed in an incubator at 25°C.
  • a lactic acid bacteria culture filtrate was added to a commercially available granule-type feed used in Thailand to an extent that the feed was sufficiently soaked to prepare an orally administered composition for breeding shrimps.
  • NITE BP-03200 and NITE BP-03201 were used as lactic acid bacteria.
  • a lactic acid bacteria culture filtrate was prepared from a lactic acid bacteria culture solution with a turbidity of about 10 OD at a wavelength of 600 nm.
  • MRS Broth which is a medium for lactic acid bacteria
  • Fig. 5 shows the shrimp survival rate from the start of infection.
  • Experiment 8 Verification of EMS/AHPND preventive or therapeutic effect by oral administration of lactic acid bacteria
  • a different method from Experiment 7 was used to prepare an orally administered composition for raising shrimps. This was orally administered to shrimp to verify the effect of suppressing infectious diseases.
  • the shrimp breeding environment and the Vibrio spp. used were the same as in Experiment 7.
  • Granule-type feed was pulverized, 24 mL of culture filtrate of NITE BP-03201 was added to 20 g of feed, kneaded, molded with a pasta machine, and dried at 60° C. for about 2 hours.
  • NITE BP-03201 culture filtrate was prepared from a lactic acid bacteria culture with a turbidity of about 10 OD at a wavelength of 600 nm. Feeding of this orally administered composition was started 3 days before the infection experiment and was continued during the infection test. As a negative control, shrimp were fed normal chow. Vibrio spp. was added to the artificial seawater to 2.6 ⁇ 10 5 cfu/mL, and the shrimp was immersed for 6 hours, after which the aerator was replaced. FIG. 6 shows the number of surviving shrimps up to 14 days after the start of infection.
  • the survival rate of the shrimp was about 30%, whereas in the group administered an orally administered composition for breeding shrimps containing a culture of NITE BP-03201 , the shrimp survival rate was 60%.
  • the bacterial cell culture of NITE BP-03201 does not lose its antibacterial activity against Vibrio spp. even after being subjected to high-temperature treatment and drying treatment. (EMS/AHPND) can be prevented or treated.
  • lactic acid bacteria culture filtrate was prepared from a lactic acid bacteria culture solution with a turbidity of about 10 OD at a wavelength of 600 nm. After that, 0.25 mL of a 2 ⁇ 10 9 cfu/mL Vibrio bacterium solution was added to the breeding water.
  • the mixture was aerated with an air stone for 3 hours, and after 3 hours, the air stone was changed to a filter (Suisaku Eight M size). Twenty-four hours after the start of infection with Vibrio, 10 mL of the lactic acid bacteria culture filtrate was further added to the breeding water. Table 9 shows the number of surviving shrimps up to 6 days after the start of infection.
  • Vibrio bacteria solution 12 agar medium, 13 lactic acid bacteria culture filtrate, 14 growth inhibition circle, 15 filter paper disc.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Insects & Arthropods (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/JP2022/027145 2021-07-09 2022-07-08 エビ目の生物の飼育用組成物、およびエビ目感染症に対する予防または治療用組成物 Ceased WO2023282354A1 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1020247003673A KR20240032900A (ko) 2021-07-09 2022-07-08 새우목 생물의 사육용 조성물, 및 새우목 감염증에 대한 예방 또는 치료용 조성물
EP22837768.5A EP4368201A4 (en) 2021-07-09 2022-07-08 Composition for rearing an organism of the order Decapoda and composition for preventing or treating infections in decapodas
CN202280048094.2A CN117677300A (zh) 2021-07-09 2022-07-08 十足目的生物的饲养用组合物和针对十足目感染症的预防或治疗用组合物
CA3226312A CA3226312A1 (en) 2021-07-09 2022-07-08 Composition for rearing organism belonging to order decapoda and composition for preventing or treating infection in decapods
AU2022308954A AU2022308954A1 (en) 2021-07-09 2022-07-08 Composition for rearing organism belonging to order decapoda and composition for preventing or treating infection in decapods
JP2023533203A JPWO2023282354A1 (https=) 2021-07-09 2022-07-08
US18/576,842 US20240335486A1 (en) 2021-07-09 2022-07-08 Composition for rearing organism belonging to order decapoda and composition for preventing or treating infection in decapods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021114165 2021-07-09
JP2021-114165 2021-07-09

Publications (1)

Publication Number Publication Date
WO2023282354A1 true WO2023282354A1 (ja) 2023-01-12

Family

ID=84800781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/027145 Ceased WO2023282354A1 (ja) 2021-07-09 2022-07-08 エビ目の生物の飼育用組成物、およびエビ目感染症に対する予防または治療用組成物

Country Status (8)

Country Link
US (1) US20240335486A1 (https=)
EP (1) EP4368201A4 (https=)
JP (1) JPWO2023282354A1 (https=)
KR (1) KR20240032900A (https=)
CN (1) CN117677300A (https=)
AU (1) AU2022308954A1 (https=)
CA (1) CA3226312A1 (https=)
WO (1) WO2023282354A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4413867A4 (en) * 2021-07-09 2025-07-02 Sumitomo Chemical Co FISH BREEDING COMPOSITION AND COMPOSITION FOR THE TREATMENT OR PREVENTION OF FISH DISEASES

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08298982A (ja) * 1995-05-02 1996-11-19 Aasu Giken:Kk 複合微生物製剤
WO2004084922A1 (ja) * 2003-03-26 2004-10-07 Takeda Food Products, Ltd. 魚介類用感染防御剤
JP2007236386A (ja) * 2006-02-09 2007-09-20 Nippon Suisan Kaisha Ltd 海藻粉末と乳酸菌を添加した養魚用飼料
JP2009159955A (ja) * 2007-12-12 2009-07-23 Kyushu Medical:Kk クルマエビ腸内から分離したプロバイオティクス乳酸菌
JP2015137254A (ja) 2014-01-22 2015-07-30 國立台湾海洋大學ＮａｔｉｏｎａｌＴａｉｗａｎ Ｏｃｅａｎ Ｕｎｉｖｅｒｓｉｔｙ エビにおけるビブリオ感染に対するワクチン及びその作製方法
WO2019059027A1 (ja) 2017-09-19 2019-03-28 ネオファーマジャパン株式会社 ５－アミノレブリン酸を含むエビ目用組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104195068A (zh) * 2014-07-25 2014-12-10 青岛尚德生物技术有限公司 一种用于预防和治疗对虾早期死亡综合症的复合微生态制剂及其应用
CN109207401A (zh) * 2018-10-10 2019-01-15 湛江恒兴养殖技术服务有限公司 拮抗凡纳滨对虾肠道内副溶血弧菌的菌株及其筛选方法
EP4174167A4 (en) * 2020-06-29 2025-01-01 Sumitomo Chemical Company, Limited Novel microorganism belonging to genus lactobacillus, and agent and method for controlling plant disease caused by ralstonia solanacearum or ralstonia pseudosolanacearum

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08298982A (ja) * 1995-05-02 1996-11-19 Aasu Giken:Kk 複合微生物製剤
WO2004084922A1 (ja) * 2003-03-26 2004-10-07 Takeda Food Products, Ltd. 魚介類用感染防御剤
JP2007236386A (ja) * 2006-02-09 2007-09-20 Nippon Suisan Kaisha Ltd 海藻粉末と乳酸菌を添加した養魚用飼料
JP2009159955A (ja) * 2007-12-12 2009-07-23 Kyushu Medical:Kk クルマエビ腸内から分離したプロバイオティクス乳酸菌
JP2015137254A (ja) 2014-01-22 2015-07-30 國立台湾海洋大學ＮａｔｉｏｎａｌＴａｉｗａｎ Ｏｃｅａｎ Ｕｎｉｖｅｒｓｉｔｙ エビにおけるビブリオ感染に対するワクチン及びその作製方法
WO2019059027A1 (ja) 2017-09-19 2019-03-28 ネオファーマジャパン株式会社 ５－アミノレブリン酸を含むエビ目用組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARROWFELTHAM: "Cowan and Steel's Manual for the Identification of Medical Bacteria", 1993, CAMBRIDGE UNIVERSITY PRESS
NAKAGAWA YASUYOSHI ET AL.: "Identification Manual of Actinomycetes", 2001, BUSINESS CENTER FOR ACADEMIC SOCIETIES, article "Gene Analysis Method - Nucleotide Sequence Determination Method for 16S rRNA Gene, edited by The Society for Actinomycetes Japan", pages: 88 - 117
See also references of EP4368201A4
SUDARAT CHOMWONG ET AL., DEVELOPMENT AND COMPARATIVE IMMUNOLOGY, vol. 89, 2018, pages 54 - 65
SUDARAT CHOMWONG ET AL., DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, vol. 89, 2018, pages 54 - 65

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4413867A4 (en) * 2021-07-09 2025-07-02 Sumitomo Chemical Co FISH BREEDING COMPOSITION AND COMPOSITION FOR THE TREATMENT OR PREVENTION OF FISH DISEASES

Also Published As

Publication number Publication date
CA3226312A1 (en) 2023-01-12
JPWO2023282354A1 (https=) 2023-01-12
KR20240032900A (ko) 2024-03-12
EP4368201A4 (en) 2025-06-25
CN117677300A (zh) 2024-03-08
AU2022308954A1 (en) 2024-01-25
EP4368201A1 (en) 2024-05-15
US20240335486A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
Meidong et al. Evaluation of probiotic Bacillus aerius B81e isolated from healthy hybrid catfish on growth, disease resistance and innate immunity of Pla-mong Pangasius bocourti
Yang et al. Lactic acid bacteria, Enterococcus faecalis Y17 and Pediococcus pentosaceus G11, improved growth performance, and immunity of mud crab (Scylla paramamosain)
Boonthai et al. Probiotic bacteria effects on growth and bacterial composition of black tiger shrimp (Penaeus monodon)
CN103403146B (zh) 用于针对弧菌的生物控制的益生菌
Fang et al. Effects of Lactobacillus pentosus HC-2 on the growth performance, intestinal morphology, immune-related genes and intestinal microbiota of Penaeus vannamei affected by aflatoxin B1
EP2836082A2 (en) Microbial strains and their use in animals
JP2009159955A (ja) クルマエビ腸内から分離したプロバイオティクス乳酸菌
RU2555549C2 (ru) ШТАММ Bacillus sp. ДЛЯ БИОЛОГИЧЕСКОЙ БОРЬБЫ С Saprolegnia sp. И ЕГО ПРИМЕНЕНИЯ
WO2024147326A1 (ja) エビ目の生物におけるウイルス感染症に対する予防または治療用経口投与組成物
Purivirojkul Application of probiotic bacteria for controlling pathogenic bacteria in fairy shrimp Branchinella thailandensis culture
JP2010051247A (ja) 病原細菌ならびに真菌に対して抗菌作用を示すバチルス・アミロリケファシエンスを有効成分とする生物的防除剤
Feliatra et al. Phylogenetic analysis to compare populations of acid tolerant bacteria isolated from the gastrointestinal tract of two different prawn species Macrobrachium rosenbergii and Penaeus monodon
EP2659786A2 (en) Probiotic food suitable for salmonid fish species and the preparation thereof
Ebnetorab et al. Isolation, biochemical and molecular detection of Bacillus subtilis and Bacillus licheniformis from the digestive system of rainbow trout (Oncorhynchus mykiss) and its inhibitory effect on Aeromonas hydrophila
WO2023282354A1 (ja) エビ目の生物の飼育用組成物、およびエビ目感染症に対する予防または治療用組成物
EP3168292B1 (en) New lactobacillus plantarum strain amt14 and composition containing the strain of lactobacillus plantarum amt14
EP4413867A1 (en) Fish rearing composition, and composition for treating or preventing fish diseases
Dosta et al. Bacteria with probiotic capabilities isolated from the digestive tract of the ornamental fish Pterophyllum scalare
Perrino et al. Bacteria with Probiotic Capabilities Isolated from the Digestive Tract of the Ornamental Fish Pterophyllum scalare
CN112940998B (zh) 一种用于预防细菌性疾病的菌株及应用
George et al. Development and evaluation of the efficacy of a local probiotic in comparison with a commercial probiotic in the African catfish, Clarias gariepinus
US20250161376A1 (en) Fish rearing composition, and composition for preventing or treating fish diseases
KR20240166096A (ko) 신규한 시포비리대 박테리오파지 vB_VhaS-MS01 및 이의 비브리오 균 증식 억제 용도
SKKU n of Str and hea Macro

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22837768

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280048094.2

Country of ref document: CN

Ref document number: 2401000067

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: 3226312

Country of ref document: CA

Ref document number: 2023533203

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2022308954

Country of ref document: AU

Ref document number: AU2022308954

Country of ref document: AU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024000127

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2022308954

Country of ref document: AU

Date of ref document: 20220708

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20247003673

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022837768

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022837768

Country of ref document: EP

Effective date: 20240209

ENP Entry into the national phase

Ref document number: 112024000127

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240104

WWW Wipo information: withdrawn in national office

Ref document number: 2022837768

Country of ref document: EP